Hepatic extraction ratio of 5-fluorouracil in rats: Dose dependence and effect of uracil and interleukin-2

Biochemical Pharmacology

Volumn 52, Issue 4, 1996, Pages 561-568

  Fuse, Eiichi ^a   Takai, Katsumi ^a   Okuno, Kiyotaka ^b   Kobayashi, Satoshi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Hepatic extraction; Immunochemotherapy; Interleukin 2; Pharmacokinetics; Uracil

Indexed keywords

FLUOROURACIL; INTERLEUKIN 2; MITOMYCIN C; TEGAFUR; URACIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; FLUOROURACIL; INTERLEUKIN-2; LIVER; MALE; RATS; RATS, WISTAR;

EID: 0030006697     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00307-3     Document Type: Article

References (57)

1. Diasio RB and Harris BE, Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 16: 215-237, 1989.
2. Sotos GA, Grogan L and Allegra CJ, Antitumour treatment. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 20: 11-49, 1994.
3. Pinedo HM and Peters GJ, Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
4. Mahmoud Y and Sadée W. The fluoropyrimidines. In: Pharmacokinetics of Anticancer Agents in Humans (Eds. Ames MM, Powis G and Kovach JS), pp. 209-227. Elsevier Science Publishers B.V., Amsterdam, 1983.
5. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, Steele G and Frei E, A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 38: 3784-3792, 1978.
6. Wagner JG, Gyves JW, Stetson PL, Walker-Andrews SC, Wollner IS, Cochran MK and Ensminger WD, Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46: 1499-1506, 1986.
7. Peters GJ, Schornagel JH and Milano GA, Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17: 123-156, 1993.
8. Boublil JL, Milano G, Khater R, Bourry J, Thyss A, Bruneton JN, Renée N, Philip C and Namer M, Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: Pharmacokinetic evaluation. Br J Cancer 52: 15-20, 1985.
9. Ubhi SS, Hollingworth J, Horsburgh T, Veitch PS, Roest G, Palmer P, Franks CR and Bell PRF, Evaluation of the safety of recombinant interleukin-2 (rIL-2) and rIL-2 plus 5-fluorouracil (5-FU) in the adjuvant treatment of gastric cancer patients. Anticancer Res 12: 749-752, 1992.
10. Reid I, Sharpe I, Maxwell W, McDevitt J, Franks CR, Tanner WA and Monson JRT, A phase 2 trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma. Eur J Surg Oncol 18: 591-598, 1992.
11. Hamblin TJ, Sadullah S, Williamson P, Stevenson J, Oskam R, Palmer P and Franks CR, A phase-III study of recombinant interleukin-2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. Br J Cancer 68: 1186-1189, 1993.
12. Okuno K, Hirohata T, Nakamura K, Jinnai H, Shigeoka H, Koh K, Shindo K and Yasutomi M, Hepatic arterial infusions of interleukin-2-based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer. Clin Ther 15: 672-683, 1993.
13. Watanabe M, Kawano Y, Kubota T, Kurihara N, Nishibori H, Hoshiya Y, Teramoto T and Kitajima M, Mechanism of synergistic antitumor effects of mitomycin-C, 5-fluorouracil and interleukin-2 against human colon cancer. Proc Am Assoc Cancer Res 36: 299, 1995.
14. Okuno K, Ohnishi H, Nakajima I, Akabane Y, Kurooka K, Koh K, Shindo K and Yasutomi M, Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: Reports of three cases. Jpn J Surg 24: 80-84, 1994.
15. Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J and Paradise C, Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 10: 207-213, 1991.
16. Trump DL, Egorin MJ, Forrest A, Willson JKV, Remick S and Tutsch KD, Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9: 2027-2035, 1991.
17. Peters GJ and Rustum YM, Novel approaches to selective treatment of human solid tumors: Laboratory and clinical correlation. Ann Oncol 4: 277-281, 1993.
18. Hines JD, Adelstein DJ, Spiess JL, Giroski P and Carter SG, Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma: Plasma and tissue pharmacokinetics. Cancer 63: 1022-1025, 1989.
19. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R and Mathé G, Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: A pilot study. Cancer Treat Rep 66: 1803-1807, 1982.
20. Madajewics S, Petrelli N, Rustum YM, Campbell J, Herrera L, Mittelman A, Perry A and Creaven PJ, Phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 44: 4667-4669, 1984.
21. - precursors. Cell Immunol 141: 323-331, 1992.
22. Park KGM, Heys SD, Murray JB, Hayes PD, Ashby JA, Franks CR and Eremin O, Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity. Cancer Immunol Immunother 35: 53-58, 1992.
23. Rosenstein M, Ettinghausen SE and Rosenberg SA, Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137: 1735-1742, 1986.
24. Gazit Z and Kedar E, Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice. Cancer Immunol Immunother 38: 243-252, 1994.
25. Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Hotter M, Walter J and Keder E, Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol Immunother 35: 135-144, 1992.
26. Elsässer-Beile U, von Kleist S, Lindenthal A, Birken R, Gallati H and Mönting JS, Cytokine production in whole blood cell cultures of patients undergoing therapy with biological response modifiers or 5-fluorouracil. Cancer Immunol Immunother 37: 169-174, 1993.
27. Balaji KN and Nayak R, Effect of 5-fluorouracil on interleukin-2 expression. Biochem Biophys Res Commun 187: 305-309, 1992.
28. Wakizaka Y, Yang Z, Hosokawa M, Hata Y and Uchino J, Host immunological status modification by various chemotherapeutic drugs. Jpn J Cancer Chemother 20: 1450-1452, 1993.
29. Mihich E, Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity. NCI Monogr 34: 90-102, 1971.
30. Fujii S, Ikenaka K, Fukushima M and Shirasaka T, Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69: 763-772, 1978.
31. Yokota T, Iga S, Awazu S and Hanano M, Simple method of hepatic venous blood sampling in the rat. J Appl Physiol 41: 439-441, 1976.
32. Kobayashi S, Takai K, Iga T and Hanano M, Pharmacokinetic analysis of the disposition of valproate in pregnant rats. Drug Metab Dispos 19: 972-976, 1991.
33. Myers CE, The pharmacology of the fluoropyrimidines. Pharmacol Rev 33: 1-15, 1981.
34. Daher GC, Harris BE and Diasio RB, Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48: 189-222, 1990.
35. Bronk JR, Lister N and Lynch S, Absorption of 5-fluorouracil and related pyrimidines in rat small intestine. Clin Sci 72: 705-716, 1987.
36. Wohlhueter RM, Mclvor RS and Plagemann PGW, Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 104: 309-319, 1980.
37. Davies B and Morris T, Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095, 1993.
38. Peters GJ, Laurensse E, Leyva A, Lankelma J and Pinedo HM, Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46: 20-28, 1986.
39. Fukushima M, Shirakawa T and Fujii S, Metabolism of 5-fluorouracil in sensitive and resistant tumor cells. Gann 70: 47-53, 1979.
40. Mulkins MA and Heidelberger C, Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 32: 965-973, 1982.
41. Naguib FNM, el Kouni MH and Cha S, Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412, 1985.
42. Tuchman M, Ramnaraine ML and O'Dea RF, In vitro degradation of pyrimidine bases: Studies of rat liver dihydropyrimidine dehydrogenase. Adv Exp Med Biol 195: 245-248, 1986.
43. Queener SF, Morris HP and Weber G, Dihydrouracil dehydrogenase activity in normal, differentiating, and regenerating liver and hepatomas. Cancer Res 31: 1004-1009, 1971.
44. Ho DH, Townsend L, Luna MA and Bodey GP, Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6: 781-784, 1986.
45. Milano G and Etienne M-C, Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (Review). Anticancer Res 14: 2295-2298, 1994.
46. Unemi N and Takeda S, Studies on combination therapy with 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil. II, Effects of uracil on in vitro metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 5-fluorouracil. Chemotherapy 29: 176-184, 1981.
47. Meerten E, Verweij J and Schellens JHM, Antineoplastic agents. Drug interactions of clinical significance. Drug Saf 12: 168-182, 1995.
48. Bligh HFG, Bartozek A, Robson CN, Hickson ID, Kasper CB, Beggs JD and Wolf CR, Activation of mitomycin C by NADPH:cytochrome P-450 reductase. Cancer Res 50: 7789-7792, 1990.
49. Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris A and Hickson ID, Decreased NADPH: cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res 50: 4692-4697, 1990.
50. Siegel D, Gibson NW, Preusch PC and Ross D, Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483-7489, 1990.
51. Dulhanty AM and Whitmore GF, Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res 51: 1860-1865, 1991.
52. Siegel D, Beall H, Senokowitsch C, Kasai M, Arai H, Gibson NW and Ross D, Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 31: 7879-7885, 1992.
53. 5 reductase. Cancer Res 53: 4907-4912, 1993.
54. Pan SS, Andrews PA and Glover CJ, Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH:cytochrome P450 reductase and xanthine oxidase. J Biol Chem 259: 959-966, 1984.
55. Gustafson DL and Pritsos SA, Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions. Cancer Res 53: 5470-5474, 1993.
56. 14C-labeled recombinant human interleukin-2 in the rat. Lymphokine Cytokine Res 11: 229-233, 1992.
57. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC and Rosenberg SA, In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135: 2865-2875, 1985.